Back to search

Peptide record

TPDB04932

Brevinin-2DYb Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
33 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB04932
Brevinin-2DYb
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 Antifungipept ToxinPred 3.0
standard
No
A 33-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC
Physicochemical Analysis
C145H250N40O42S2
RHIMPTWY
G
3289.94
9.65
5
2
13
+3
4.50
0.397
112.12
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
125
3.80
6
Residue Composition
number
2
A
0
R
1
N
1
D
2
C
1
E
1
Q
7
G
0
H
0
I
6
L
5
K
0
M
1
F
0
P
2
S
0
T
0
W
0
Y
4
V
Amino Acid Distribution
A: 2 R: 0 N: 1 D: 1 C: 2 E: 1 Q: 1 G: 7 H: 0 I: 0 L: 6 K: 5 M: 0 F: 1 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 4
Chemical Descriptors
33
C145H250N40O42S2
3289.94
9.65
+3
4.50
0.397
Free
L
Linear
Free
Anticancer
Rana dybowskii
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50 = 24.01 µM
Anticancer
24.01 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 37.84 µM
Anticancer
37.84 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 3 Activity

Activity

IC50
IC50 = 23.26 µM
Anticancer
23.26 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 4 Activity

Activity

IC50
IC50 = 35.05 µM
Anticancer
35.05 µM

Target

Colon Cancer
LoVo
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 5 Activity

Activity

IC50
Toxicity
50.66 µM
Cytotoxic
IC50 | 50.66 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides. | Int J Mol Sci | 2021
Evidence 6 Activity

Activity

<10% Hemolysis
Toxicity
256 µM
Hemolytic Cytotoxic
<10% Hemolysis | 256 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides. | Int J Mol Sci | 2021